Development and Evaluation of Etodolac Osmotic Capsule

controlled release formulations have been developed based on their significant advantages over conventional immediate release dosage forms, such as the decrease of dosing frequency, the increase of patient compliance, better dosing patterns, the reduction of side effects, or the maintenance of the drug concentration within a desired range, i.e., an overall improved therapeutic benefit. However, oral controlled release formulations are exposed to changing environment during transit through the GI-tract which may affect their performances e.g. physiological factors such as patient age or food-intake. Reported as releasing drug independently of these factors, oral osmotically-driven systems (OODS) have taken an integral place in the pharmaceutical field. The dissolution profile of orally delivered drugs can be controlled through the use of osmotically controlled drug delivery devices. The most commonly used device is the osmotic tablet/Capsule, which is essentially a tablet/Capsule core that is coated with a rate-limiting semipermiable membrane. Using osmotic pressure as driving force, various OCODDS design and compositions have been developed. Numerous products are launched based on these systems. In present investigation attempts are taken to formulate, optimize and develop an economic osmotically controlled Capsule containing drugs belonging to non steroidal anti-inflammatory category to release the drug in controlled manner. Such formulations are most beneficial for the patients shifted on long term pain management therapy(e.g. in arthritis) in view to reduce the associated side effects of these drugs.